This Article Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Braunschweiger, P. G. Search for Related Content PubMed PubMed Citation Articles by Braunschweiger, P. G.

Effect of Cyclophosphamide on the Pathophysiology of RIF-1 Solid Tumors¹

AMC Cancer Research Center, Lakewood, Colorado 80214

The present experiments were conducted to determine the effects of cyclophosphamide (150 mg/kg) on the pathophysiology of RIF-1 solid tumors and to determine the temporal relationship between treatment mediated changes in tumor vascular physiology, cell proliferation, and chemoresponsiveness in vivo. Capillary permeability and plasma and extracellular water volumes were determined by a ¹²⁵I-bovine serum albumin, ⁵¹Cr-EDTA double isotope dilution assay at various intervals after cyclophosphamide. Tumor blood flow and exchangeable erythrocyte vascular volumes were determined by ³⁶RbCl distribution and ⁵¹Cr-labeled erythrocyte dilution methods.

Cell proliferation in RIF-1 tumors, assessed by [³H]thymidine labeling index and tumor growth fraction (primer-dependent DNA polymerase labeling assay) measurements, was inhibited for up to 3 days by cyclophosphamide. Although tumor regrowth was not apparent until Day 10, cell kinetic studies indicated proliferative recovery in the surviving cell population on Days 4 and 5 after treatment. Increases in tumor blood flow and tumor vascular volumes were temporally coincident with this proliferative response. In split-dose experiments, the time-dependent increases in the chemoresponsiveness of RIF-1 tumors, after cyclophosphamide, may be due not only to the increased proliferation of repopulating cells, but also to vascular responses attendant with cytoreduction.

¹ This work was supported by a gift to the AMC Cancer Research Center from John E. Fuller, Sr., and by CA39596 awarded by the Department of Health, Education, and Welfare.

Received 4/ 6/87. Revised 3/18/88. Accepted 4/26/88.

This article has been cited by other articles:

				H. Poptani, N. Bansal, W. T. Jenkins, D. Blessington, A. Mancuso, D. S. Nelson, M. Feldman, E. J. Delikatny, B. Chance, and J. D. Glickson Cyclophosphamide Treatment Modifies Tumor Oxygenation and Glycolytic Rates of RIF-1 Tumors: 13C Magnetic Resonance Spectroscopy, Eppendorf Electrode, and Redox Scanning Cancer Res., December 15, 2003; 63(24): 8813 - 8820. [Abstract] [Full Text] [PDF]

				L. A. Santana-Blank, E. Rodriguez-Santana, F. Vargas, H. Reyes, P. Fernandez-Andrade, S. Rukos, and K. E. Santana-Rodriguez Phase I Trial of an Infrared Pulsed Laser Device in Patients with Advanced Neoplasias Clin. Cancer Res., October 1, 2002; 8(10): 3082 - 3091. [Abstract] [Full Text] [PDF]

				U. Duvvuri, H. Poptani, M. Feldman, L. Nadal-Desbarats, M. S. Gee, W. M. F. Lee, R. Reddy, J. S. Leigh, and J. D. Glickson Quantitative T1{rho} Magnetic Resonance Imaging of RIF-1 Tumors in Vivo: Detection of Early Response to Cyclophosphamide Therapy Cancer Res., November 1, 2001; 61(21): 7747 - 7753. [Abstract] [Full Text] [PDF]

				P. M. J. McSheehy, M. O. Leach, I. R. Judson, and J. R. Griffiths Metabolites of 2'-Fluoro-2'-deoxy-D-glucose Detected by 19F Magnetic Resonance Spectroscopy in Vivo Predict Response of Murine RIF-1 Tumors to 5-Fluorouracil Cancer Res., April 1, 2000; 60(8): 2122 - 2127. [Abstract] [Full Text]